The Food and Drug Administration today announced the expansion of its emergency use authorization for Pfizer’s COVID-19 vaccine to include adolescents ages 12 to 15. The expansion comes ahead of Wednesday’s convening of the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices, whose recommendation will be an important part of CDC’s decision on whether to recommend vaccination for that age group.
 
The FDA has updated the Pfizer vaccine-specific Fact Sheets for Healthcare Providers Administering the Vaccine (Vaccination Providers) and for Recipients and Caregivers with information to reflect the use of the vaccine in the adolescent population.
 

Related News Articles

Headline
The Centers for Disease Control and Prevention today released updated guidance for clinicians treating COVID-19 in patients who received the Pfizer COVID-19…
Headline
Pfizer’s COVID-19 vaccine booster for children under age 5 was 80.3% effective and well tolerated in a clinical trial involving 1,678 children who received the…
Headline
The Centers for Disease Control and Prevention yesterday recommended children age 5-11 receive a booster dose five months after completing the Pfizer COVID-19…
Headline
U.S. residents can order online eight more free at-home tests for COVID-19, the White House announced yesterday. People who have difficulty accessing the…
Headline
The Food and Drug Administration today authorized a single Pfizer COVID-19 booster dose for children aged 5-11 who completed the Pfizer vaccine primary series…
Headline
The Food and Drug Administration yesterday approved using Olumiant (baricitinib) to treat COVID-19 in hospitalized adults requiring supplemental oxygen,…